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Abstract
Introduction: We prospectively evaluated whether hepatic steatosis (HS) and the presence of carotid plaques (CPs)
impacts on achieving minimal disease activity (MDA) in psoriatic arthritis (PsA) patients starting tumor necrosis
factor (TNF)-a blockers treatment.
Methods: Before starting treatment with TNF-a blockers, consecutive PsA subjects with an active disease were
evaluated for the presence of the metabolic syndrome (MetS), HS and CPs. The incidence of MDA was evaluated
12 and 24 months later.
Results: Among 270 PsA subjects, 91 (33.7%) exhibited the MetS, 58 (21.5%) CPs and 76 (28.1%) HS. At the 12-month
follow-up, 98 (36.3%) individuals achieved MDA. Compared with those who did, a higher prevalence of the MetS, HS
and CPs was found in subjects who did not achieve the MDA (P always < 0.001). After adjusting for the MetS and for
all the other demographic/clinical characteristics analyzed, the presence of HS and CPs at baseline independently
predicted the risk of not achieving MDA (Hazard Ratio: 1.91, 95% confidence interval (CI): 1.04 to 3.38, P = 0.035 and
Hazard Ratio: 3.21, 95%CI: 1.64 to 6.29, P = 0.001, respectively). Separate Kaplan-Meier survival models confirmed this
(Log-Rank: 12.894, P < 0.001 and Log-Rank: 12.849, P < 0.001, respectively). Compared with those without,
progressively increasing Hazard Ratios of not achieving MDA were found in those with HS, CPs or HS + CPs at
baseline. Moreover, the presence of HS and/or CPs predicted the risk of relapse during the additional 12-month
follow-up (Hazard Ratio: 2.85, 95%CI: 1.27 to 6.37, P = 0.011 and Hazard Ratio: 3.17, 95%CI: 1.57 to 6.41, P = 0.001
respectively).
Conclusions: HS and/or CPs at baseline are negative predictors of achieving and maintaining MDA.
Introduction
Psoriatic arthritis (PsA) is a chronic arthropathy associated
with psoriasis, marked by an axial and/or peripheral joint
involvement [1]. In addition to joint manifestations, sub-
jects with PsA exhibit an abnormally high cardiovascular
(CV) risk and, in turn, risk of the metabolic syndrome
(MetS), one of its major vascular risk factors (VRFs) [2,3].
Accordingly, as compared with healthy controls, PsA
patients exhibit a higher than normal platelet reactivity [4]
and a higher than normal prevalence of hepatic steatosis
(HS) [5] and of carotid plaques (CPs) [6]. All these condi-
tions are well known markers of atherosclerosis and of CV
risk [7,8].
Chronic inflammation may interact with VRFs, leading
to a further increase of the CV risk in PsA patients [9,10].
In addition to being involved in the inflammatory process,
most cytokines (TNF-a, IL-1, IL-6) play a role in the gen-
esis and in the progression of atherosclerosis [11]. Both
HS and CPs are strongly influenced by the severity of
chronic inflammation [12-15] and are directly correlated
with the MetS and its features.
Compared with those with minimal disease activity
(MDA), PsA subjects with an active disease show an exag-
gerated worsening of HS degree [16] and an increased
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prevalence of CPs [17]. Thus, in addition to being asso-
ciated with a cardio-metabolic impairment, CPs and/or
HS may be markers of the severity of the inflammatory
process in PsA subjects [12-15].
In view of this, we prospectively evaluated whether,
regardless of the presence of MetS, the presence of HS
and/or CPs at baseline impacts per se on the achieving
of MDA in subjects with PsA who start a treatment
with TNF-a blockers.
Materials and methods
During a three-year period (January 2007 to January 2010),
all patients with a diagnosis of PsA (according to the Clas-
sification Criteria for Psoriatic Arthritis (CASPAR) cri-
teria) [1] who were non-responders to traditional disease
modifying anti-rheumatic drugs (DMARDs) and who were
referred to the Regional Reference Center for the treat-
ment of spondyloarthropathies of the Federico II Univer-
sity of Naples to start treatment with TNF-a blockers,
were evaluated for enrollment in this study. For all
enrolled subjects, exclusion criteria were: lack of informed
consent signature, age < 18 years, previous treatment with
TNF-a blockers, adequate clinical response to traditional
DMARDs treatment, malignancy, hematologic diseases,
autoimmune diseases other than PsA, unstable medical
conditions, ongoing pregnancy, history of venous and/or
arterial thrombosis and of alcohol abuse. After approval of
the study by the local Ethics Committee and after
informed consent signature, data about age, gender,
height, weight, disease duration, disease activity, previous
and/or current treatments and vascular risk factors were
collected from all patients as previously described [13]. All
PsA subjects had clinically active disease at the time of
enrollment and were classified into different clinical sub-
sets (Moll and Wright criteria) [18]. Briefly, PsA patients
were classified as having axial disease if they had at least
grade 2 unilateral sacroiliitis in the presence of a combina-
tion of inflammatory back pain plus back stiffness. The
PsA patients were classified as pure axial if they had no
peripheral joint involvement, mixed if they had both per-
ipheral joint arthritis and axial disease, or as having only
peripheral joint involvement. The rare mutilans form was
diagnosed in the presence of distal interphalangeal joint
bone resorption (osteolysis), ‘pencil-in-cup’ radiographic
findings or telescoping motion of the digit. According
to the National Cholesterol Education Program (NCEP)
criteria [19], abdominal obesity was defined as a waist cir-
cumference ≥102 cm for men and ≥88 cm for women;
hypertriglyceridemia, as triglyceride levels ≥150 mg/dL;
hypercholesterolemia with low-HDL cholesterol as a total
cholesterol ≥200 mg/dL with HDL-cholesterol < 40 mg/dL
for men and < 50 mg/dL for women; hypertension as a
blood pressure ≥130 and/or 85 mmHg; and impaired fast-
ing glucose (IFG) as a fasting glucose ≥100 mg/dL.
Patients were defined as having the MetS if three or more
of these VRFs were present. In addition, the presence of
CPs and the presence/severity of HS were evaluated in
each PsA subject according to previously validated scan-
ning protocols [13,16]. All the carotid artery ultrasound
examinations were performed by the same operator. After
a five minute rest in the supine position, the subjects
underwent a bilateral carotid ultrasonography (US) with a
7.5 to 12 MHz linear-array transducer and a duplex scan-
ner (ESAOTE MyLab 25Gold, Genoa, Italy). The ultra-
sound evaluation was performed longitudinally and
transversally by using gray-scale and color-Doppler US
imaging. The scan protocol requires the full-length visuali-
zation of the near and far wall of the right and left com-
mon carotid artery (CCA) and of the bulb in three
different projections (anterior, lateral and posterior). The
intima-media thickness (IMT) was measured in each of
the three projections in the CCA and bulb and the pre-
sence of CPs was defined for IMT ≥1.3 mm. The reprodu-
cibility of the vascular measurement was evaluated in 20
subjects within 1 week from the first ultrasonographic
examination. The overall Pearson’s r value for the IMT
measurements was 0.89 (P < 0.001). The presence of HS
was assessed with a US diagnostic system (Logiq P5, Gen-
eral Electric, Milan, Italy) with a 3.5-MHz convex probe.
All the US determinations were made by the same trained
operator. The intra-operator variability, as evaluated in 20
subjects within 1 week from the first ultrasonographic
examination, showed an overall r value of 0.92 (P < 0.001).
As previously validated [16], the presence/severity of HS
was defined by comparing the echogenicity of the liver
and of the kidney cortex: Grade 0 (absent): iso-echogeni-
city; Grade 1 (mild): diffuse and homogeneous hyper-
echogenicity; Grade 2 (moderate): attenuation of the ultra-
sonic beam rear; Grade 3 (severe): lack of diaphragm pro-
file visualization. The presence of CPs and of a moderate/
severe (2nd/3rd degree) HS were recorded in all subjects at
baseline (T0). At T0 as well as every three months after
having started the treatment with TNF-a blockers, all PsA
subjects underwent a complete clinical rheumatologic and
laboratory evaluation that included: tender joint count
(TJC, n = 78), swollen joint count (SJC, n = 76), tender
entheseal count (according to the Maastricht Ankylosing
Spondylitis Enthesitis Score), psoriasis area severity index
(PASI), health assessment questionnaire (HAQ), visual
analog scale for pain (VAS), patient global disease activity
VAS score, erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP). The data obtained at 12 months
were recorded as (T1). During the first 12 months of fol-
low-up (from T0 to T1), PsA subjects were classified as
having achieved MDA when fulfilling 5 or more of the fol-
lowing 7 outcome measures at T1: TJC ≤1; SJC ≤1; PASI
≤1 or body surface area ≤3; VAS for pain ≤15; patient glo-
bal disease activity VAS score of ≤20; HAQ ≤0.5 and
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tender entheseal points ≤1 [20]. Otherwise, they were con-
sidered as not having achieved MDA (non-MDA). To test
the achieving of sustained-MDA (s-MDA), those who had
achieved MDA, were re-evaluated every 3 months there-
after during the additional 12-months (T2). s-MDA was
defined as fulfilling the same criteria employed for MDA
in all the visits carried out between T1 and T2.
The present study protocol has been approved by the
Federico II University Local Ethic Committee.
Statistical analysis
Statistical analysis was performed with the SPSS 16 sys-
tem (SPSS Inc., Chicago, IL, USA). Continuous data
were expressed as means ± SD; categorical variables
were expressed as percent. The t-test was performed to
compare continuous variables; the chi-square test was
employed to analyze categorical data. When the mini-
mum expected value was < 5, the Fisher’s exact test was
used.
A Kaplan-Meier survival model (with the Log-Rank
test) was adopted to evaluate the cumulative achieving
MDA according to the presence of HS or CPs. To adjust
for all the other variables (with emphasis on the pre-
sence of the MetS) and to evaluate the achieving of
MDA (or of s-MDA), separate COX regression analyses
(stepwise method) were adopted, with the achieving
MDA (or s-MDA) as the dependent variable and the
MetS, CPs, HS, number of CV risk markers, obesity,
hypertension, hypercholesterolemia, hypertriglyceride-
mia, impaired fasting glucose, smoking habit, TJC, SJC,
tender entheseal count, PASI, HAQ, VAS for pain,
patient global VAS, ESR, CRP, concomitant treatment
with methotrexate, gender, age and disease duration as
independent variables. Multi-collinearity effect in multi-
variable regression models was excluded by a stepwise
approach with each variable included for P < 0.05 and
excluded for P > 0.1. A tolerance test was employed to
exclude models in which the sum of the values exceeded
the sum of the variances for all variables. All the results
are presented as two-tailed values with statistical signifi-
cance if P values < 0.05.
As to the sample size calculation, to plan a study with
a minimal pre-defined Hazard Ratio (HR) ≥1.4, an
accrual interval of 3 years, and a follow-up period of
24 months, at least 222 subjects are needed to achieve a
> 80% power with an 5% a error. With an expected
drop-out of 25% during the follow-up, 280 subjects were
enrolled in the study.
Results
After excluding those already under treatment with TNF-a
blockers (n = 224) and those with adequate clinical
response to traditional DMARDs treatment (n = 545), 280
PsA subjects were enrolled in this study. Of these, 10 were
missed during the follow-up (because of missing baseline
data, missing follow-up visits, premature withdrawal of
treatment with TNF-a blockers). Thus, 270 PsA subjects,
completing their follow-up, were included in the analysis.
Their clinical and demographic characteristics are reported
in Table 1.
As to the use of TNF-a blockers, adalimumab (40 mg/
every 2 weeks) was employed in 80 subjects (29.6%);
etanercept (50 mg/week) in 111 (41.1%) and infliximab (5
mg/kg every 8 weeks) in 79 subjects (29.3%). A MetS was
diagnosed in 84 (31.1%) subjects. The presence of CPs
and of HS was found in 36 (13.3%) and 71 (26.3%) sub-
jects, respectively. On the other hand, 163 (60.4%) PsA
subjects did not have CPs or HS; 80 (29.6%) had either
one of the two, and 27 (10%) had both. A direct correla-
tion was found between CRP and ESR with the IMT
values (r = 0.531, P < 0.001 and r = 0.476, P < 0.001).
Whereas no difference in the prevalence of HS was found
Table 1 Clinical and demographic characteristics of the
study population
Variable PsA subjects (number = 270)
Male gender 124 (45.9%)
Age (years) 51.73 ± 11.49
Disease subset







Concomitant MTX 111 (41.1%)
Disease duration (years) 4.87 ± 2.94
ESR (mm/h) 18.05 ± 13.19
CRP (mg/L) 2.64 ± 2.93
SJC 3.77 ± 4.08
TJC 11.93 ± 5.48
PASI 1.48 ± 0.71
HAQ 2.47 ± 1.45
VAS 76.7 ± 20.12
Patient global VAS 74.25 ± 22.38
Tender entheseal count 10.97 ± 5.40
Hypercholesterolemia 139 (51.5%)
Hypertriglyceridemia 92 (34.1%)
Impaired fasting glucose 20 (7.4%)
Hypertension 57 (21.1%)
Smoking habit 65 (24.1%)
Obesity 111 (41.1%)
CPs, presence of carotid plaques (carotid intima-media thickness > 1.3 mm);
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; HS, hepatic steatosis; MetS, metabolic syndrome;
MTX: Methotrexate; PASI, Psoriasis Area Severity Index; SJC, swollen joint
count; TJC, tender joint count; VAS, Visual Analogue Scale for pain.
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based on stratification according to different clinical sub-
sets (Pearson’s c2 for inter-groups independence P =
0.516), the presence of CPs was found in 10.5% of sub-
jects with peripheral subset; 14.1% of those with axial
subset, 26.3% in the axial + peripheral subset and in
87.5% of those with the mutilans subset (Pearson’s c2 for
inter-groups independence P < 0.001).
Twelve-month follow-up (T0-T1)
During the follow-up, no changes in treatment schedules
and/or in VRFs prevalence were reported in the study
population. As a whole, 98/270 (36.3%) PsA individuals,
achieving 5 or more of the minimal disease activity
criteria [20], were classified in MDA.
MDA was achieved in 33 (41.8%) subjects receiving
infliximab, in 41 (36.9%) of those receiving etanercept
and in 24 (30%) of those receiving adalimumab (Pearson’s
c2 for inter-groups independence P = 0.299). As reported
in Table 2 the prevalence of different clinical subsets did
not differ among those who achieved MDA and those
who did not. Overall, the rate of achieving MDA did not
differ according to PsA clinical subsets (Pearson’s c2 for
inter-groups independence P = 0.092).
Those who had achieved MDA were more often men
(P = 0.001) and had a younger age (P = 0.042), a longer
disease duration (P = 0.004), a higher ESR (P < 0.001)
and CRP (P < 0.001), and a lower TJC (P < 0.001) and
tender entheseal counts (P = 0.003) than those who
did not (Table 2). Conversely, the MetS, CPs and HS
(P always < 0.001) were more frequent in those who did
not achieve MDA as compared with those who did. As to
the features of the MetS, the prevalence of obesity and of
hypercholesterolemia was higher in those who did not
achieve MDA.
Separate Kaplan-Meier survival models (Figure 1)
showed a significant difference in those achieving MDA
whether or not HS (Log-Rank: 12.894, P < 0.001) and CPs
(Log-Rank: 12.849, P < 0.001) were present. After adjust-
ing for the presence of the MetS as well as for all the other
demographic characteristics and for rheumatologic and
cardiovascular variables, HS and CPs independently pre-
dicted the risk of not achieving MDA (HR: 1.91, 95%CI:
1.04 to 3.38, P = 0.035 and HR: 3.21, 95%CI: 1.64 to 6.29,
P = 0.001, respectively).
MDA was achieved by 76 (46.6%) subjects with neither
HS nor CPs, by 20 (25.0%) of those with HS or CPs and by
2 (7.4%) of those with both HS and CPs (Pearson’s c2 for
inter-groups independence P < 0.001). As compared with
those with neither HS nor CPs, a progressively increasing
HR of not achieving MDA was found in those with HS or
CPs and in those with both HS and CPs (Figure 2).
In addition to HS and CPs, male gender (HR: 2.25, 95%
CI: 1.47 to 3.43, P < 0.001), a low TJC (HR: 1.15, 95%CI:
1.08 to 1.23, P < 0.001), and a high CRP (HR: 1.18, 95%CI:
1.07 to 1.30, P < 0.001) independently predicted achieving
MDA in this regression model.
Twenty-four-month follow-up (T1-T2)
Among the 98 subjects who had achieved MDA during
the first 12 months of follow-up, 17 (17.3%) relapsed
and 81 (82.7%) maintained their MDA during the addi-
tional 12-months of follow-up (T2). In a regression
model in which only the 98 subjects who had achieved









Age (years) 52.66 ± 10.60 50.08 ± 8.81 0.042
Male gender 65 (37.8%) 59 (60.2%) 0.001
Clinical subset
Axial + Peripheral 63 (36.6%) 32(32.7%) 0.596
Peripheral 59 (34.3%) 36 (36.7%) 0.693
Axial 41 (23.8%) 23 (23.5%) 1.000
Mutilans 9(5.2%) 7(7.1%) 0.595
MetS 73(42.4%) 18(18.4%) <
0.001
HS 62(36.0%) 14(14.3%) <
0.001
CPs 48(27.9%) 10(10.2%) 0.001
Disease duration
(months)
101.72 ± 74.01 126.93 ±
58.83
0.004
ESR (mm/h) 14.35 ± 11.06 20.16 ± 13.86 <
0.001
CRP (mg/L) 1.66 ± 1.83 3.20 ± 3.28 <
0.001
SJC 3.75 ± 4.30 3.80 ± 3.68 0.929
TJC 12.99 ± 5.62 10.06 ± 4.71 <
0.001
PASI 1.49 ± 0.68 1.45 ± 0.76 0.700
HAQ 2.39 ± 1.41 2.61 ± 1.52 0.230
VAS 77.50 ± 17.30 75.30 ± 24.33 0.390
Patient global VAS 74.24 ± 21.08 74.28 ± 24.62 0.988
Tender entheseal count 11.71 ± 5.45 9.66 ± 5.06 0.003
Hypercholesterolemia 103(59.9%) 36(36.7%) <
0.001
Hypertriglyceridemia 60(34.9%) 32(32.7%) 0.790
Impaired fasting glucose 11(6.4%) 9(9.2%) 0.470
Hypertension 39(22.7%) 18(18.4%) 0.441
Smoking habit 36(20.9) 29(29.6) 0.138
Obesity 88(51.2%) 23(23.5%) <
0.001
Stratification according to the achieving of MDA at 12-month follow-up. CPs,
presence of carotid plaques (carotid intima-media thickness > 1.3 mm); CRP,
C-reactive protein; ESR, erythrocyte sedimentation rate; HAQ, Health
Assessment Questionnaire; HS, hepatic steatosis; MetS, metabolic syndrome;
PASI, Psoriasis Area Severity Index; SJC, swollen joint count; TJC, tender joint
count; VAS, Visual Analogue Scale for pain.
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MDA during the first 12-month follow-up were evalu-
ated, the presence of HS or CPs was associated with a
high risk of disease relapsing during the additional
12-months of follow-up (HR:2.85, 95%CI:1.27 to 6.37,
P = 0.011 and HR: 3.17,95%CI:1.57 to 6.41, P = 0.001,
respectively). Compared with subjects with neither HS
nor CPs, the HR of PsA relapse was higher in those with
HS or CPs (HR: 3.05, 95%CI:1.67 to 5.55, P < 0.001) and
in those with both HS and CPs (HR: 8.93, 95%CI:1.21 to
66.66, P = 0.032).
Discussion
In the setting of PsA subjects, several clinical and labora-
tory predictors of six-month and three-month response to
TNF-a blockers have been identified [21,22]. In PsA sub-
jects starting treatment with TNF-a blockers, this pro-
spective study shows that HS or CPs at baseline are
associated per se with a high risk of not achieving MDA.
A variety of variables (CRP, complement C3, IL-6 and
TNF-a) implicated in the regulation of the inflammatory
process [23] and, in turn, in the pathophysiology of
arthritides [24], are relevant in the etiology and the
development of atherosclerosis [25-27]. Major markers
of atherosclerosis (HS and CPs) that assess the global
damage due to metabolic and inflammatory determi-
nants [14] are affected in PsA subjects [9,13,16].
Accordingly, subjects who exhibit a high prevalence of
HS and of CPs are likely to have experienced a more
severe inflammatory state [12-15].
Among the 98/270 PsA patients who achieved MDA
at 12 months, the prevalence of HS and of CPs was sig-
nificantly lower than in those who did not. Accordingly,
the presence of one of these atherosclerosis markers was
associated with a high risk of not achieving MDA.
Moreover, the presence of HS or of CPs was associated
with a poor probability of sustained MDA at the 24-
month follow-up. However, because of the relatively
small number of patients included in this sub-analysis,
the evaluation of the impact of CPs and/or HS on
achieving sustained MDA, although statistically signifi-
cant, should be considered only as a proof of concept.
The combined data lend credence to the possibility
that the presence of CPs and/or HS is a negative predic-
tor of achieving and maintaining MDA.
Figure 1 Kaplan-Meier survival model for achieving minimal disease activity (MDA) according to the presence of CPs and HS. CPs,
presence of carotid plaques (carotid intima-media thickness > 1.3 mm); HS, hepatic steatosis; MDA, minimal disease activity.
Figure 2 Risk of not achieving minimal disease activity (MDA)
at 12-month follow-up according to the presence of HS and/or
CPs. 95%CI, 95% confidence interval; CPs, presence of carotid
plaques (carotid intima-media thickness > 1.3 mm); HR, hazard ratio;
HS, hepatic steatosis; MDA, minimal disease activity.
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By evaluating such a large number of consecutive PsA
patients (270 PsA subjects), the MetS was diagnosed in
33.7%, HS was found in 28.1% and CPs in 21.5% of sub-
jects. These data are in line with previous literature data
obtained on smaller size samples [3,5,6]. Further
strengthening the link between cardiometabolic variables
and inflammation, in a previous analysis on the present
population, we have found that obesity (defined as a
Body Mass Index > 30) is associated with a statistically
significant increase in the risk of a poor treatment
response in PsA subjects receiving TNF-a blockers [28].
At variance with the already published data, in this study
the presence of obesity is defined according to the waist
circumference measurement (which is a major NCEP cri-
terion for the diagnosis of the MetS) [19]. However, as
highlighted in Table 2 also in this case, the prevalence of
obesity is higher in those not achieving MDA. Moreover,
since obesity is a major feature of the MetS, and being
known to impact on HS and CPs presence, a multivariate
regression analysis was performed to adjust all the results
of this study for the presence of MetS and of its features
and to exclude collinearity in the prediction of achieving
MDA. In this respect, we are confident to have excluded
some important bias in this study.
In addition to CPs and HS, other demographic (male
gender) and rheumatologic (CRP and TJC) variables
predicted the achieving of MDA. The relevance of CPs
and HS as MDA predictors has been adjusted (regres-
sion model) for the large majority of clinical and labora-
tory variables known to predict the achieving of MDA
[22].
All the carotid and liver ultrasound evaluations were
performed only at the study baseline evaluation. A pro-
spective evaluation of changes in these parameters during
the treatment with TNF-a blockers could have further
clarified the interrelation between IMT, HS and PsA dis-
ease activity. Although some literature data [29] suggest
that treatment with ‘biologic agents’ is associated with
the lowering of the IMT as well as of the degree of liver
steatosis, further ad hoc designed studies are needed to
address this important issue.
The link between inflammation and atherosclerosis is
strongly supported by the finding of a direct correlation
between CRP and ESR with the IMT in the present set-
ting. All these inflammatory reactants have been
included in the regression model to adjust for their
values. The finding that the achieving of MDA is
directly associated with a high CRP level and negatively
associated with HS and CPs might sound like a con-
trasting result. However, these findings are in line with
the possibility that HS and the presence of CPs are
atherosclerosis markers influenced both by inflammation
and by other variables (that is, obesity, aging) known to
negatively impact on the achieving of MDA [22,28].
Although further studies are needed to describe better
the underlying pathophysiologic mechanisms, this find-
ing suggests that the presence of HS and CPs can be
reliable markers of a cumulative (inflammatory + meta-
bolic) damage.
A noteworthy finding is that the presence of CPs was
found in 87.5% of those with the mutilans PsA subset.
Because of the rarity of this clinical subset, the number
of subjects evaluated was extremely low and no statisti-
cal inferences are possible from these data. However,
that the CPs prevalence is maximal in the most severe
PsA subset needs to be further evaluated in properly
designed studies.
A series of markers is involved in the interrelation
between inflammation and atherosclerosis [9,27]. In addi-
tion to ESR and CRP, the evaluation of TNF-a and IL-6
levels could have been of interest in the present setting.
However, these measurements were not available in all
cases.
Among PsA subjects enrolled in the present setting,
the prevalence of an axial involvement is high (23.7%).
At variance with most data in the literature, we have
enrolled subjects experiencing a failure of treatment
with traditional DMARDs and with the indication to
start treatment with TNF-a blockers. Because of its high
rate of refractoriness to DMARDs, the presence of an
axial subset has been recognized as a major criterion to
start treatment with TNF-a blockers [30]. The selection
criteria used could have caused such a high prevalence
of the axial subset in our study population. However
(Table 2), there was no significant difference in the
achieving of MDA after stratifying the population
according to the different PsA clinical subsets.
Most previous studies in PsA subjects employed differ-
ent criteria to define a good clinical response. We have
chosen the criteria of achieving MDA proven to be appro-
priate in providing an outcome measure for clinical trials
[21]. As to clinical and demographic variables known to
predict MDA, the hazard ratios found in the present study
are in line with those of previous reports [22].
In addition to their obvious pathophysiological signifi-
cance, these data may have pharmaco-economic impli-
cations [31]. Because of their high cost and their side
effects (that is, a higher than normal risk of infections
and of malignancies) [32], the identification of predic-
tors of the success of TNF-a blockers is mandatory. By
stratifying the achieving of a good clinical response, a
risk/benefit evaluation may be performed in each case
and for each patient. This, in turn, would hinder the use
of TNF-a blockers in subjects with a low probability of
success. Further studies with higher numbers of subjects
are needed to address this important issue.
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Conclusions
The presence of HS and/or CPs is a negative predictor of
achieving and maintaining MDA during treatment with
TNF-a blockers.
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